Quercetin triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts and inhibits bone resorption in RAW264.7 cells

Cellular Physiology and Biochemistry

Volumn 30, Issue 1, 2012, Pages 123-136

  Guo, Chun ^a   Hou, Guo Qing ^a   Li, Xue Dong ^a   Xia, Xue ^a   Liu, Dong Xin ^a   Huang, Dong Yang ^a   Du, Shi Xin ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Cyclooxygenase2 (COX 2); LPS; Mitogen activated protein kinases (MAPK); Osteoclast; Quercetin; Receptor activator of nuclear factor B (RANK)

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; CYCLOOXYGENASE 2; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; QUERCETIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL POPULATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84863472458     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000339052     Document Type: Article

References (51)

1. Roodman D: Advances in bone biology: the osteoclast. Endocr Rev 1996;17:308-332.
2. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie M T, Martin T J: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357. (Pubitemid 30649812)
3. Boyle W J , Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 2003;423:337-342. (Pubitemid 40852708)
4. Shuto T, Jimi E, Kukita X Hirata M, Koga T: Granulocytemacrophage colony stimulating factor suppresses lipopolysaccharide-induced osteoclast-like cell formation in mouse bone marrow cultures. Endocrinology 1994;134:831-837. (Pubitemid 24057230)
5. Abu-Amer Y, Ross FP, Edwards J , Teitelbaum SL: Lipopolysaccharide- stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 1997;100:1557-1565. (Pubitemid 27425783)
6. Islam S, Hassan F, Tumurkhuu G, Dagvadorj J , Koide N, Naiki Y, Mori I, Yoshida X Yokochi T: Bacterial lipopolysaccharide induces osteoclast formation in RAW 264.7 macrophage cells. Biochem Biophys Res Commun 2007;360:346-351. (Pubitemid 47030351)
7. Mormann M, Thederan M, Nackchbandi I, Giese X Wagner C, Hansch GM: Lipopolysaccharides (LPS) induce the differentiation of human monocytes to osteoclasts in a tumour necrosis factor (TNF) alpha-dependent manner: a link between infection and pathological bone resorption. Mol Immunol 2008;45:3330-3337.
8. Itoh K, Udagawa N, Kobayashi K, Suda K, Li X, Takami M, Okahashi N, Nishihara X Takahashi N: Lipopolysaccharide Promotes the Survival of Osteoclasts Via Toll-Like Receptor 4, but Cytokine Production of Osteoclasts in Response to Lipopolysaccharide Is Different from That of Macrophages. J Immunol 2003;170:3688-3695 (Pubitemid 36359239)
9. Takami M, Kim N, Rho J , Choi Y: Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol 2002;169:1516-1523. (Pubitemid 34809198)
10. Wattel A, Kamel S, Mentaverri R, Lorget F, Prouillet C, Petit JP, Fardelonne P, Brazier M: Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol 2003;65:35-42. (Pubitemid 35447836)
11. Woo JX Nakagawa H, Notoya M, Yonezawa X Udagawa N, Lee IS, Ohnishi M, Hagiwara H, Nagai K: Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. Biol Pharm Bull 2004;27:504-509. (Pubitemid 41701834)
12. Siddiqui JA, Swarnkar G, Sharan K, Chakravarti B, Gautam AK, Rawat P, Kumar M, Gupta V, Manickavasagam L, Dwivedi AK, Maurya R, Chattopadhyay N: A naturally occurring rare analog of quercetin promotes peak bone mass achievement and exerts anabolic effect on osteoporotic bone. Osteoporos Int 2011;22:3013-3027.
13. Gutierrez-Venegas G, Jimenez-Estrada M, Maldonado S: The effect of flavonoids on transduction mechanisms in lipopolysaccharide-treated human gingival fibroblasts. Int Immunopharmacol. 2007;7:1199-1210. (Pubitemid 47049702)
14. Kim MH, Ryu SY, Choi JS, Min YK, Kim SH. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. J Cell Physiol 2009;221:618-628.
15. Livak K J , Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001;25:402-408. (Pubitemid 34164012)
16. Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B: Bacterially induced bone destruction: Mechanisms and misconceptions. Infect Immun 1996;64:2371-2380. (Pubitemid 26226792)
17. Orcel P, Feuga M, Bielakoff J , De Vernejoul MC: Local bone injections of LPS and M-CSF increase bone resorption by different pathways in vivo in rats. Am J Physiol 1993:264:E391-E397. (Pubitemid 23103951)
18. Chiang CY, Kyritsis G, Graves DT, Amar S: Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. Infect Immun 1999;67:4231-4236. (Pubitemid 29357050)
19. Ito HO, Shuto X Takada H, Koga X Aida Y, Hirata M, Koga T: Lipopolysaccharides from Porphyromonas gingivalis, Prevotella intermedia and Actinobacillus actinomycetemcomitans promote osteoclastic differentiation in vitro. Arch oral biol 1996:41:439-444. (Pubitemid 27061182)
20. Horcajada-Molteni MN, Crespy V, Coxam V, Davicco M J , Remesy C, Barlet JP: Rutin inhibits ovariectomy-induced osteopenia in rats. J Bone Miner Res 2000;15:2251-2258.
21. Hee Do S, DVM, Lee JW, Jeong WI, Chung JY, Park S J , Hong IH, Jeon SK, Lee IS, Jeong KS: Bone-protecting effect of Rubus coreanus by dual regulation of osteoblasts and osteoclasts. Menopause 2008;15:676-668.
22. Hollman PCH, Gaag MVD, Mengelers MJB, et al. Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Rad Biol Med 1996;21:703-707. (Pubitemid 26331100)
23. Hollman PCH, van Trijp JMP, Mengelers MJB, et al. Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett 1997;114:139-140. (Pubitemid 27140094)
24. Halleen JM, Raisanen S, Salo J J , Reddy SV, Roodman GD, Hentunen TA, Lehenkari PR Kaija H, Vihko R Vaananen HK: Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1999;274:22907-22910.
25. Angel NZ, Walsh N, Forwood MR, Ostrowski MC, Cassady Al, Hume DA: Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J Bone Miner Res 2000;15:103-110. (Pubitemid 30026937)
26. Reponen R Sahlberg C, Munaut C, Thesleff I, Tryggvason K: High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 1994;124:1091-1102. (Pubitemid 24109410)
27. Yu X, Huang Y, Collin-Osdoby R Osdoby P: Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 2003;18:1404-1418. (Pubitemid 41070795)
28. Samanna V, Ma T, Mak TW, Rogers M, Chellaiah MA: Actin polymerization modulates CD44 surface expression, MMP-9 activation, and osteoclast function. J Cell Physiol 2007;213:710-720. (Pubitemid 350058264)
29. Wilson SR, Peters C, Saftig R Bromme D: Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 2009;284:2584-2592.
30. Ishikawa T, Kamiyama M, Tani-Ishii N, Suzuki H, Ichikawa Y, Hamaguchi Y, Momiyama N, Shimada H: Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides. Mol Carcinog 2001;32:84-91.
31. Kozloff KM, Quinti L, Patntirapong S, Hauschka PV, Tung CH, Weissleder R, Mahmood U: Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo. Bone 2009;44:190-198.
32. Stern PH: Antiresorptive agents and osteoclast apoptosis. J Cell Biochem 2007; 101:1087-1096. (Pubitemid 47253712)
33. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22: 153-183. (Pubitemid 32458157)
34. Xia Z, Dickens M, Raingeaud J , Davis R J , Greenberg ME: Opposing effects of ERK and J NK-p38 MAP kinases on apoptosis. Science 1995;270:1326-1331.
35. Fister S, Giinthert AR, Aicher B, Paulini KW, Emons G, Griindker C: GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res 2009;69:6473-6481.
36. Park GB, Kim YS, Lee HK, Song H, Cho DH, Lee W J , Hur DY: Endoplasmic reticulum stress-mediated apoptosis of EBV-transformed B cells by cross-linking of CD 70 is dependent upon generation of reactive oxygen species and activation of p38 MAPK and JNK pathway. J Immunol 2010;185:7274-7284.
37. Li L, Pettit AR, Gregory LS, Forwood MR. Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name.Cytokine Growth Factor Rev 2006;17:203-216. (Pubitemid 43816896)
38. Ono K, Akatsu T, Murakami T, Kitamura R, Yamamoto M, Shinomiya N, Rokutanda M, Sasaki T, Amizuka N, Ozawa H, Nagata N, Kugai N: Involvement of cyclooxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 2002;17:774-781. (Pubitemid 34441893)
39. Ono K, Akatsu T, Kugai N, Pilbeam CC, Raisz LG: The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines. Bone 2003;33:798-804. (Pubitemid 37393491)
40. Kellinsalmi M, Parikka V, Risteli J , Hentunen T, Leskela HV, Lehtonen S, Selander K, Vaananen K, Lehenkari P: Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro. Eur J Pharmacol 2007;572:102-110. (Pubitemid 47429646)
41. Armstrong AR Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC: A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002;277:44347-44356. (Pubitemid 36157870)
42. Crockett JC, Mellis D J , Scott DI, Helfrich MH: New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int 2011;22:1-20.
43. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos A J , Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle W J , Penninger JM: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
44. Kim N, Odgren PR, Kim DK, Marks SC Jr, Choi Y: Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000;97:10905-10910.
45. Li J , Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J , Martin L, Christensen K, McCabe J , Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ: RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-1571. (Pubitemid 30118482)
46. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J , Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey P J , Peschon J J , Schuh J : RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424. (Pubitemid 29453612)
47. Li P, Schwarz EM, O'Keefe R J , Ma L, Boyce BF, Xing L: RANK signaling is not required for TNFalpha-mediated increase in CD11 (hi) osteoclast precursors but is essential for mature osteoclast formation in TNF alpha-mediated inflammatory arthritis. J Bone Miner Res 2004;19:207-213. (Pubitemid 38116734)
48. Feeley BT, Liu NQ, Conduah AH, Krenek L, Roth K, Dougall WC, Huard J , Dubinett S, Lieberman JR: Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and RANKFc administration. J Bone Miner Res. 2006;21:1571-1580. (Pubitemid 44484602)
49. Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe R J , Boyce BF, Schwarz EM: In vivo RANK signaling blockade using the receptor activator of NF-KB:FC effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 2002;17:192-199. (Pubitemid 34087651)
50. Kim H, Choi HK, Shin JH, Kim KH, Huh JY, Lee SA, Ko CY, Kim HS, Shin HI, Lee H J , Jeong D, Kim N, Choi Y, Lee SY: Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J Clin Invest 2009a;119:813-825.
51. Poblenz AT, Jacoby J J , Singh S, Darnay BG: Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides. Biochem Biophys Res Commun 2007;359:510-515. (Pubitemid 46898981)